Meyer Debra
Department of Biochemistry, University of Johannesburg, P.O. Box 524 Auckland Park 2006, Gauteng Province, South Africa.
Curr Pharm Des. 2006;12(16):1943-7. doi: 10.2174/138161206777442164.
Iron chelators, as treatment for conditions of iron overload, have implications for AIDS and tuberculosis (TB) since excess iron in the system assists HIV and Mycobacterium tuberculosis (M.tb) multiplication. Excess iron, especially due to dietary habits, is almost as common in sub-Saharan Africa as infections by the two organisms. That HIV and M.tb influence each other's replication during co-infection is well established, but in vitro evaluations of concurrent infection of the two under conditions of iron overload and determining whether chelators reverse the effect, are limited. This review provides brief commentary on the possibility of iron chelators presently in clinical use influencing simultaneous HIV-M.tb infections during iron loading and the feasibility of evaluating this in vitro.
铁螯合剂作为治疗铁过载病症的药物，对艾滋病和结核病（TB）有影响，因为体内过量的铁会促进艾滋病毒和结核分枝杆菌（M.tb）的繁殖。过量的铁，尤其是由于饮食习惯导致的，在撒哈拉以南非洲几乎与这两种病原体的感染一样普遍。艾滋病毒和结核分枝杆菌在共同感染期间相互影响彼此的复制，这一点已得到充分证实，但在铁过载条件下对两者同时感染进行体外评估以及确定螯合剂是否能逆转这种影响的研究有限。本综述简要评论了目前临床使用的铁螯合剂在铁负荷期间影响艾滋病毒与结核分枝杆菌同时感染的可能性以及在体外进行评估的可行性。
